NCT04754685

Platelet-rich Plasma and Synovial Cytokines in Knee Osteoarthritis

Completed NA Last updated 15 February 2021

What this trial tests

NA trial testing Intra-articular injection of platelet-rich plasma in Knee Osteoarthritis in 90 participants. Completed in 14 March 2020.

Timeline

1 February 2019

Primary endpoint
31 January 2020

14 March 2020

Quick facts

Lead sponsor	South Valley University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	90
Start date	1 February 2019
Primary completion	31 January 2020
Estimated completion	14 March 2020
Sites	1 location across Egypt

Drugs / interventions tested

• Intra-articular injection of platelet-rich plasma — full drug profile →

Conditions studied

• Knee Osteoarthritis — all drugs for Knee Osteoarthritis →

Sponsor

South Valley University

Who can join

Adults 25 to 65, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective study was performed on 90 patients were included and categorized into mild (30 cases, moderate (30 cases) and severe (30 cases) knee OA. Three intra-articular (I.A) injections of PRP, 2 weeks a part, were received. Pain score and MRI Osteoarthritis Knee Score (MOAKS) were assessed. Serial synovial fluid cytokines assays in the form of Tumor necrosis factor-α (TNF-α) and Macrophage migration inhibitory factor (MIF), were performed using commercially available ELISA assay kits. The assays were performed pre-injection (S1), two weeks from the 1st I.A injection and two weeks from the 2nd I.A injection (S3) for all included patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.